Herpes Simplex Encephalitis Treatment & Management

  • Author: Wayne E Anderson, DO; Chief Editor: Karen L Roos, MD   more...
 
Updated: Jun 17, 2011
 

Approach Considerations

A high index of suspicion is required to make the diagnosis of herpes simplex encephalitis (HSE), and expeditious evaluation is indicated after the diagnosis is considered. In the absence of any other identifiable cause, consider HSE in any febrile patient with encephalopathy and CSF pleocytosis. Start empiric acyclovir therapy promptly in patients with suspected HSE pending confirmation of the diagnosis because acyclovir, the drug of choice, is relatively nontoxic and because the prognosis for untreated HSE is poor.

Failure to consider the possibility of HSE can result in delayed diagnosis and treatment, with subsequent increased risks of mortality and morbidity. A single-center study from a high-volume academic emergency department (ED) reported that only 29% of patients with a presentation suggestive of viral encephalitis (fever, neuropsychiatric abnormalities, cerebrospinal fluid [CSF] pleocytosis, and a negative CSF Gram stain) received acyclovir in the ED.[37]

See the following for more information:

Next

Initial Management

Prehospital care consists of supportive management of the patient’s airway, breathing, and circulation (ABCs). General nutritional and fluid support is important. Universal precautions are appropriate. Monitor for increased intracranial pressure (ICP) and seizures.

Intensive care unit (ICU) care may be required, especially if seizure activity or increased ICP is present. Depending on the availability of local expertise (eg, infectious disease, neurology, neurosurgery specialists), transfer to a tertiary care facility may be appropriate. Hospitalization is not routine for uncomplicated herpes simplex virus type 1 (HSV-1) or herpes simplex virus type 2 (HSV-2) infection.

Management of increased intracranial pressure

Treatment of brain edema ranges from simple measures (eg, elevating head of bed, gentle diuresis with medication such as furosemide) to more complex measures (eg, mannitol and steroids, intubation with hyperventilation).

Management of seizures

Behavioral manifestations of HSE may resemble seizures, which are also common. Should seizure activity become apparent or should electroencephalography (EEG) show evidence of nonconvulsive seizures, begin anticonvulsant therapy.

Benzodiazepines may be useful for aborting status epilepticus but, because of their short duration, are ineffective at preventing further seizures. A longer-acting agent is preferable.

Previous
Next

Antiviral Therapy

Pharmacotherapy for HSE is available in the form of acyclovir. Patient outcome is improved after treatment with this agent. Acyclovir is the treatment of choice for HSE.[1, 3, 38] When the diagnosis of HSE is suspected or has been established, acyclovir (typically 30 mg/kg/d intravenously [IV] in adults) should be initiated immediately.

Through a series of in vivo reactions catalyzed by viral and host cellular enzymes, acyclovir is converted to acyclovir triphosphate, a potent inhibitor of HSV DNA polymerase, without which viral replication cannot occur. Human cells are not affected.

Acyclovir has relatively few serious adverse effects. Because of its high pH, IV acyclovir may cause phlebitis and local inflammation if extravasation occurs. Gastrointestinal (GI) disturbances, headache, and rash are among the more frequent adverse reactions.

The drug is excreted by the kidney, and the dose should be reduced in patients with renal dysfunction. Crystal-induced nephropathy may occur if the maximum solubility of free drug is exceeded. Risk factors for this are IV administration, rapid infusion, dehydration, concurrent use of nephrotoxic drugs, underlying renal disease, and high doses. The risk of renal toxicity is reduced by adequately hydrating the patient (eg, 1 mL/d of fluid for each 1 mg/d of acyclovir).

Acyclovir is considered appropriate for serious infections during pregnancy. The manufacturer cautions that it should be used in pregnancy only when the potential benefits outweigh the potential risks. However, a prospective registry of acyclovir use in pregnancy between 1984 and 1999, including 756 first-trimester exposures, demonstrated a 3.2% rate of birth defects, similar to that expected in the general population.[39]

In immunocompetent patients, viral resistance to acyclovir has been clinically insignificant, with a reported prevalence of less than 1%.[40] However, in immunocompromised patients, this figure rises to 6%. Degree of immunosuppression and duration of exposure to acyclovir appear to be the most important risk factors for the development of resistant strains.

Since most relapses occur within 3 months of completing an initial course of IV acyclovir, a prolonged course of an oral antiviral agent (eg, valacyclovir) has been suggested after initial treatment. An ongoing clinical trial is currently evaluating a 90-day course of valacyclovir versus placebo after treatment with acyclovir in patients with HSE.[41]

A 2009 Cochrane database review of data from 17 trials that compared interventions used for the prevention and treatment of HSV in patients being treated for cancer concluded that acyclovir is effective in preventing and treating HSV infections. Valacyclovir was not found to be more effective than acyclovir, nor did a higher dose of valacyclovir make a difference. Some evidence indicated that placebo, as a prophylaxis, is more effective than prostaglandin E, but the risk of bias was unclear in all trials.[42]

If long-term suppressive therapy is needed, acyclovir or famciclovir can be used orally.

Neonatal herpes simplex encephalitis

Acyclovir in doses of 20 mg/kg IV every 8 hours (60 mg/kg/d) is currently recommended for neonatal HSE. This dosage is higher than that used in older children and adults (30 mg/kg/d), but, in neonates, it has been shown to improve mortality and morbidity when compared with the lower dosage. Because the higher dosage is associated with neutropenia, the white blood cell (WBC) count should be monitored closely.

Previous
Next

Steroid Therapy

The role of steroids in the treatment of HSE remains uncertain. To the extent that cellular damage in HSE is the result of immune-mediated inflammatory processes triggered by the viral infection, the anti-inflammatory effects of steroids may be beneficial. However, there is also concern that steroids might suppress immune responses of the host that are necessary to limit viral replication.

Animal studies have demonstrated a beneficial effect of steroids on outcome, without evidence of increased viral replication or dissemination.[43, 44] Steroids have been used to reduce cerebral edema in patients with severe HSE.

One nonrandomized, retrospective human study compared the outcomes of patients with HSE who received steroids in addition to acyclovir with the outcomes of those who received acyclovir alone.[45] The steroid group had improved outcomes at 3 months. Although these results suggest a possible role for steroids in HSE, definitive recommendations must await the results of larger prospective studies.

The German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE), a multicenter, randomized, placebo-controlled trial, is currently enrolling patients with HSE in a study designed to assess the outcomes of treatment with acyclovir against the outcomes of treatment with acyclovir plus dexamethasone.[46]

Previous
Next

Prevention

No measures are known to be effective for preventing HSE in adults and older children. Person-to-person transmission does not occur. Prophylactic treatment of close contacts and special isolation precautions are unnecessary.

Preventive measures for neonatal HSE include cesarean delivery in women with active herpetic genital infections at the time of delivery and protection of neonates from persons with active herpetic infections. Some authorities recommend a course of suppressive acyclovir therapy near the time of delivery in mothers with a history of genital herpes.

Previous
Next

Consultations and Additional Care

HSE is a neurologic emergency. Consultation with a neurologist is required. Neurosurgical consultation is helpful only if a brain biopsy is being considered. An infectious disease consultation may be appropriate.

An evaluation for rehabilitation is often appropriate to deal with the long-term neurologic sequelae of HSE. Depending on the nature and degree of any neurologic deficits present, rehabilitation services may be required.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Wayne E Anderson, DO  Assistant Professor of Internal Medicine/Neurology, College of Osteopathic Medicine of the Pacific Western University of Health Sciences; Clinical Faculty in Family Medicine, Touro University College of Osteopathic Medicine; Clinical Instructor, Departments of Neurology and Pain Management, California Pacific Medical Center

Wayne E Anderson, DO is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Law, Medicine & Ethics, California Medical Association, and San Francisco Medical Society

Disclosure: Cephalon Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; King Honoraria Speaking and teaching; Forest Honoraria Speaking and teaching

Specialty Editor Board

Ramon Diaz-Arrastia, MD, PhD  Professor, Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Southwestern Medical School; Director, North Texas TBI Research Center, Comprehensive Epilepsy Center, Parkland Memorial Hospital

Ramon Diaz-Arrastia, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, New York Academy of Sciences, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

Karen L Roos, MD  John and Nancy Nelson Professor of Neurology, Professor of Neurological Surgery, Department of Neurology, Indiana University School of Medicine

Karen L Roos, MD is a member of the following medical societies: American Academy of Neurology and American Neurological Association

Disclosure: Nothing to disclose.

References

  1. Whitley RJ. Herpes simplex encephalitis: adolescents and adults. Antiviral Res. Sep 2006;71(2-3):141-8. [Medline].

  2. Whitley RJ, Kimberlin DW. Herpes simplex encephalitis: children and adolescents. Semin Pediatr Infect Dis. Jan 2005;16(1):17-23. [Medline].

  3. Tyler KL. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's. Herpes. Jun 2004;11 Suppl 2:57A-64A. [Medline].

  4. Wasay M, Mekan SF, Khelaeni B, Saeed Z, Hassan A, Cheema Z, et al. Extra temporal involvement in herpes simplex encephalitis. Eur J Neurol. Jun 2005;12(6):475-9. [Medline].

  5. Aurelian L. HSV-induced apoptosis in herpes encephalitis. Curr Top Microbiol Immunol. 2005;289:79-111. [Medline].

  6. DeBiasi RL, Kleinschmidt-DeMasters BK, Richardson-Burns S, Tyler KL. Central nervous system apoptosis in human herpes simplex virus and cytomegalovirus encephalitis. J Infect Dis. Dec 1 2002;186(11):1547-57. [Medline].

  7. Esiri MM. Herpes simplex encephalitis. An immunohistological study of the distribution of viral antigen within the brain. J Neurol Sci. May 1982;54(2):209-26. [Medline].

  8. Cinque P, Vago L, Marenzi R, Giudici B, Weber T, Corradini R, et al. Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. Clin Infect Dis. Aug 1998;27(2):303-9. [Medline].

  9. Fodor PA, Levin MJ, Weinberg A, Sandberg E, Sylman J, Tyler KL. Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology. Aug 1998;51(2):554-9. [Medline].

  10. Osih RB, Brazie M, Kanno M. Multifocal herpes simplex virus type 2 encephalitis in a patient with AIDS. AIDS Read. Feb 2007;17(2):67-70. [Medline].

  11. Baringer JR, Pisani P. Herpes simplex virus genomes in human nervous system tissue analyzed by polymerase chain reaction. Ann Neurol. Dec 1994;36(6):823-9. [Medline].

  12. Mitchell BM, Stevens JG. Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response. J Immunol. Jan 1 1996;156(1):246-55. [Medline].

  13. Geiger KD, Nash TC, Sawyer S, Krahl T, Patstone G, Reed JC, et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology. Nov 24 1997;238(2):189-97. [Medline].

  14. Cathomas R, Pelosi E, Smart J, Murray N, Simmonds P. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer. Clin Oncol (R Coll Radiol). Jun 2005;17(4):292-3. [Medline].

  15. Kohl S. Herpes Simplex Virus. In: Behrman RE, Kliegman RM, Jenson HB. Behrman: Nelson Textbook of Pediatrics. 17th ed. Philadelphia: Saunders; 2004.

  16. Kimberlin D. Herpes simplex virus, meningitis and encephalitis in neonates. Herpes. Jun 2004;11 Suppl 2:65A-76A. [Medline].

  17. Whitley RJ, Soong SJ, Dolin R, Galasso GJ, Ch'ien LT, Alford CA. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study. N Engl J Med. Aug 11 1977;297(6):289-94. [Medline].

  18. Utley TF, Ogden JA, Gibb A, McGrath N, Anderson NE. The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol. Jul 1997;10(3):180-9. [Medline].

  19. Elbers JM, Bitnun A, Richardson SE, Ford-Jones EL, Tellier R, Wald RM, et al. A 12-year prospective study of childhood herpes simplex encephalitis: is there a broader spectrum of disease?. Pediatrics. Feb 2007;119(2):e399-407. [Medline].

  20. Shelley BP, Raniga SB, Al-Khabouri J. An unusual late complication of intracerebral haematoma in herpes encephalitis after successful acyclovir treatment. J Neurol Sci. Jan 31 2007;252(2):177-80. [Medline].

  21. Marschitz I, Rödl S, Gruber-Sedlmayr U, Church A, Giovannoni G, Zobel G, et al. Severe chorea with positive anti-basal ganglia antibodies after herpesencephalitis. J Neurol Neurosurg Psychiatry. Jan 2007;78(1):105-7. [Medline]. [Full Text].

  22. Sköldenberg B, Aurelius E, Hjalmarsson A, Sabri F, Forsgren M, Andersson B, et al. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. Feb 2006;253(2):163-70. [Medline].

  23. Whitley RJ, Cobbs CG, Alford CA Jr, Soong SJ, Hirsch MS, Connor JD, et al. Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA. Jul 14 1989;262(2):234-9. [Medline].

  24. Whitley RJ, Soong SJ, Linneman C Jr, Liu C, Pazin G, Alford CA. Herpes simplex encephalitis. Clinical Assessment. JAMA. Jan 15 1982;247(3):317-20. [Medline].

  25. Ku A, Lachmann EA, Nagler W. Selective language aphasia from herpes simplex encephalitis. Pediatr Neurol. Sep 1996;15(2):169-71. [Medline].

  26. McGrath NM, Anderson NE, Hope JK, Croxson MC, Powell KF. Anterior opercular syndrome, caused by herpes simplex encephalitis. Neurology. Aug 1997;49(2):494-7. [Medline].

  27. Mondal G, Kumar R, Ghosh JK, Basu K, Chatterjee S. Basal ganglia involvement in a child with herpes simplex encephalitis. Indian J Pediatr. Jul 2009;76(7):749-50. [Medline].

  28. Li JZ, Sax PE. HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person. AIDS Read. Apr 2009;19(4):153-5. [Medline].

  29. Benetó A, Gómez E, Rubio P, Sobrino R, Esparza A, Gil M, et al. [Periodical EEG pattern modifications in herpetic encephalitis treated with acyclovir]. Rev Neurol. Jul 1996;24(131):829-32. [Medline].

  30. Mook-Kanamori B, van de Beek D, Wijdicks EF. Herpes simplex encephalitis with normal initial cerebrospinal fluid examination. J Am Geriatr Soc. Aug 2009;57(8):1514-5. [Medline].

  31. Lakeman FD, Whitley RJ. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. Apr 1995;171(4):857-63. [Medline].

  32. Cinque P, Cleator GM, Weber T, Monteyne P, Sindic CJ, van Loon AM. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. Oct 1996;61(4):339-45. [Medline]. [Full Text].

  33. Schloss L, Falk KI, Skoog E, Brytting M, Linde A, Aurelius E. Monitoring of herpes simplex virus DNA types 1 and 2 viral load in cerebrospinal fluid by real-time PCR in patients with herpes simplex encephalitis. J Med Virol. Aug 2009;81(8):1432-7. [Medline].

  34. Domingues RB, Lakeman FD, Mayo MS, Whitley RJ. Application of competitive PCR to cerebrospinal fluid samples from patients with herpes simplex encephalitis. J Clin Microbiol. Aug 1998;36(8):2229-34. [Medline]. [Full Text].

  35. Wildemann B, Ehrhart K, Storch-Hagenlocher B, Meyding-Lamadé U, Steinvorth S, Hacke W, et al. Quantitation of herpes simplex virus type 1 DNA in cells of cerebrospinal fluid of patients with herpes simplex virus encephalitis. Neurology. May 1997;48(5):1341-6. [Medline].

  36. Weil AA, Glaser CA, Amad Z, Forghani B. Patients with suspected herpes simplex encephalitis: rethinking an initial negative polymerase chain reaction result. Clin Infect Dis. Apr 15 2002;34(8):1154-7. [Medline].

  37. Benson PC, Swadron SP. Empiric acyclovir is infrequently initiated in the emergency department to patients ultimately diagnosed with encephalitis. Ann Emerg Med. Jan 2006;47(1):100-5. [Medline].

  38. Rathmann K, Scott SA. Acyclovir. In: Drug Evaluation Monographs. Micromedex:2005.

  39. Stone KM, Reiff-Eldridge R, White AD, Cordero JF, Brown Z, Alexander ER, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. Apr 2004;70(4):201-7. [Medline].

  40. James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res. Sep 2009;83(3):207-13. [Medline]. [Full Text].

  41. National Institute of Allergy and Infectious Diseases. A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct/show/NCT00031486?order=1. Accessed August 8, 2007.

  42. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. Jan 21 2009;CD006706. [Medline].

  43. Sergerie Y, Boivin G, Gosselin D, Rivest S. Delayed but not early glucocorticoid treatment protects the host during experimental herpes simplex virus encephalitis in mice. J Infect Dis. Mar 15 2007;195(6):817-25. [Medline].

  44. Thompson KA, Blessing WW, Wesselingh SL. Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. Feb 2000;6(1):25-32. [Medline].

  45. Kamei S, Sekizawa T, Shiota H, Mizutani T, Itoyama Y, Takasu T, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. Nov 2005;76(11):1544-9. [Medline]. [Full Text].

  46. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, et al. Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. Oct 29 2008;8:40. [Medline]. [Full Text].

 
Previous
Next
 
Axial proton density-weighted image in 62-year-old woman with confusion and herpes encephalitis shows T2 hyperintensity involving right temporal lobe.
Axial gadolinium-enhanced T1-weighted image reveals enhancement of right anterior temporal lobe and parahippocampal gyrus. At right anterior temporal tip is hypointense, crescentic region surrounded by enhancement consistent with small epidural abscess.
Axial diffusion-weighted image reveals restricted diffusion in left medial temporal lobe consistent with herpes encephalitis. This patient also had positive result on polymerase chain reaction assay for herpes simplex virus, which is both sensitive and specific. In addition, patient had periodic lateralized epileptiform discharges on electroencephalography, which supports diagnosis of herpes encephalitis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.